Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
Recruiting
Early Phase 1
Interventional Study
X-Linked Retinitis Pigmentosa
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 8 – 45
- Sex
- Male
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 18 (estimated)
- Sponsor
- Frontera Therapeutics · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;
Exclusion Criteria:
1.Have other retinal degenerative diseases, such as retinal d…
Contacts